Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia

Archives of Internal Medicine

Volumn 158, Issue 9, 1998, Pages 998-1004

  Ravid, Mordchai ^a,c   Brosh, David ^b   Ravid Safran, Dorit ^a   Levy, Zohar ^a   Rachmani, Rita ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b Department of Cardiology   (Israel)

^c MEIR MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; DIABETIC NEPHROPATHY; DISEASE ASSOCIATION; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MEAN ARTERIAL PRESSURE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SOCIAL STATUS; URINARY EXCRETION;

ADULT; ALBUMINURIA; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HEMOGLOBIN A; HUMANS; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTENSION; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; SEX FACTORS; SMOKING;

EID: 0032507776     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.9.998     Document Type: Article

References (39)

1. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity onset diabetes. N Engl J Med. 1984;310:356-360.
2. Klein R, Klein BEK, Moss SE. The incidence of gross proteinuria in people with insulin-dependent diabetes mellitus. Arch Intern Med. 1991;151:1344-1348.
3. Dinneen SF, Gershein HC. The association of microalbuminuria and mortality in non-insulin-dependent diabetes mellitus. Arch Intern Med. 1997;157:1413-1418.
4. Mauer SM, Chavers BM. A comparison of kidney disease in type I and type II diabetes. In: Vranic M, Hollenberg CH, Steiner G, eds. Comparison of Type I and Type II Diabetes: Similarities in Etiology, Pathogenesis, and Complications. New York, NY: Plenum Press; 1985:299-303. Advances in Experimental Medicine and Biology; Vol 186.
5. Hasslacher C, Ritz E, Wahl P, Michael C. Similar risks of nephropathy in patients of type I or type II diabetes mellitus. Nephrol Dial Transplant. 1989;4:859-863.
6. Pugh JA, Medina R, Ramirez M. Comparison of the course to end-stage renal disease of type I (insulin-dependent) and type II (non-insulin-dependent) diabetic nephropathy. Diabetologia. 1993;36:1094-1098.
7. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
8. Feldt-Rasmussen B, Mathiesen ER, Jensen T, Lauritzen T, Deckert T. Effect of improved metabolic control on loss of kidney function in type I (insulin-dependent) diabetic patients: an update of the Steno Studies. Diabetologia. 1991;34:164-170.
9. Brinchmann-Hansen O, Dahl-Jorgensen K, Sadvik L, Hanssen KF. Blood glucose concentrations and progression of diabetic retinopathy: the seven year results of the Oslo Study. BMJ. 1992;304:19-22.
10. Reichard P, Nilsson BY, Rosenqvist M. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304-309.
11. Krolewski AS, Laffel LMB, Krolewski M, Quinn M. Warram JH. Glycosylated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med. 1995;332:1251-1255.
12. The Diabetes Control and Complications Trial Research Group. The absence of glycemic threshold for the development of long term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes. 1966;215:1289-1298.
13. Viberti GC. A glycemic threshold for diabetic complications? N Engl J Med. 1995;332:1293-1295.
14. Pinho-Silveiro S, Friedman R, Gross JL. Glomerular hyperforation in NIDDM patients without overt proteinuria. Diabetes Care. 1993;16:115-119.
15. Pinho-Silveiro S, Friedman R, Jobin de Azeredo M, Canati LH, Gross JL. Five-year prospective study of glomerular filtration rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes Care. 1996;19:171-174.
16. Suraniti S, Bled F, Girault A, Fressinaud P, Marre M. Serum lipids and urinary albumin excretion in non-insulin-dependent diabetics. Mol Cell Biochem. 1992;109:197-200.
17. Lee ET, Lee VS, Lu M, Lee JS, Russel D, Yeh J. Incidence of renal failure in NIDDM: the Oklahoma Indian Diabetes Study. Diabetes. 1994;4:572-579.
18. Ohkudo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with noninsulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995;28:103-117.
19. Hellman R, Regan J, Rosen H. Effect of intensive treatment of diabetes on the risk of death or renal failure in NIDDM and IDDM. Diabetes Care. 1997;20:258-264.
20. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med. 1996:124(1 pt 2):136-145.
21. Viberti GC, Mogensen CE, Passa P, Bilous R, Mangili R. St Vincent Declaration 1994: guidelines for the prevention of diabetic renal failure. In: Mogensen CE, ed. The Kidney and Hypertension in Diabetes Mellitus. Boston, Mass: Kluwer Academic Publishers; 1994:522.
22. WHO Expert Committee on Diabetes Mellitus. Second Report of the WHO Expert Committee on Diabetes Mellitus. Geneva, Switzerland: World Health Organization; 1980. Technical Reports Series No. 646.
23. Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med. 1993;118:577-581.
24. Ravid M, Lang R, Rachmani R, Lishner M. Long term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med. 1996;156:286-289.
25. Bartels H, Bohmer M, Heierl C. Serum creatinine determination without protein precipitation. Clin Chim Acta. 1972;:37:193-197.
26. Allain CC, Poon LS, Chan CSG, Richmond W, Fu PC. Enzymatic determination of total serum cholesterol. Clin Chem. 1974;10:470-475.
27. Badham D, Trinder P. An improved color reagent for the determination of blood glucose by the oxidose system. Analyst. 1972;97:142-145.
28. Sathianathan P, Rege VP, Barron JL. Immunoturbidimetric determination of urinary albumin with a centrifugal analyzer. Clin Chem. 1986;32:202.
29. Mitch NE, Nalser M, Buffington GA, Lemman J Jr. A simple method of estimating progression of chronic renal failure. Lancet. 1976;2:1326-1328.
30. SAS/STAT Software: Calls and Logistic Procedures, Release 6.04. Cary, NC: SAS Institute Inc; 1990.
31. Ulm K. A statistical method for assessing a threshold in epidemiological studies. Stat Med. 1991;10:341 -349.
32. Jones RH, Molitoris BA. A statistical method for determining the breakpoint of two lines. Anal Biochem. 1984;141:287-290.
33. National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension. 1994;23:145-158.
34. Ravid M, Savin H, Lang R, Jutrin I, Ludvinovsky S, Lishner M. Proteinuria, renal impairment, metabolic control and blood pressure in type 2 diabetes mellitus: a 14-year follow-up report on 195 patients. Arch Intern Med. 1992;152:1225-1229.
35. Mulec H, Johnsen SA, Wiklund O, Bjorck S. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22:196-201.
36. Ravid M, Neuman L, Lishner M. Plasma lipids and the progression of nephropathy in diabetes mellitus type II: effect of ACE inhibitors. Kidney Int. 1995;47:907-910.
37. Wirta OR, Pasternack AI, Mustoren JT, Koivula TA, Harmoinen A. Urinary albumin excretion rate and its determinants after six years in non-insulin-dependent diabetic patients. Nephrol Dial Transplant. 1996;11:449-456.
38. Colwell JA. DCCT findings: applicability and implications for NIDDM. Diabetes Rev. 1994;:2:277-291.
39. Colwell JA. The feasibility of intensive insulin management in non-insulin-dependent diabetes mellitus: implications of the Veterans Affairs Cooperative Study on Glycemic Control and Complications in NIDDM. Ann Intern Med. 1996:124 (1 pt 2):131-135.